[A clinical study on cefteram pivoxil in pediatrics]. 1989

Y Satoh, and K Ishikawa, and S Iwata, and H Akita, and K Sunakawa
Department of Pediatrics, Ohta General Hospital.

Clinical evaluations of cefteram pivoxil (CFTM-PI, T-2588) were carried out. The obtained results are summarized as follows. 1. Clinical responses to CFTM-PI of 39 patients with pediatric infections were excellent in 16, good in 21, fair in 1 and poor in 1. The overall efficacy rate was 94.9%. 2. Bacteriologically, eradication rates for 39 isolates presumed to be pathogens were evaluated. The eradication rates obtained were 94.1% in 17 strains of Gram-positive cocci, 90.9% in 22 strains of Gram-negative rods. 3. Side effects observed were diarrhea in 2 patients, diarrhea and abdominal pain in 1, erythema and edema in 1. The incidence was 8.7%. An abnormal value found in clinical laboratory tests was eosinophilia in 1 patient. The results suggested that CFTM-PI might be a very useful and safe drug for the treatment of pediatric infections.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001424 Bacterial Infections Infections by bacteria, general or unspecified. Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases
D015281 Cefmenoxime A cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date no severe side effects have been noted. Abbott-50192,Cefmax,Cefmenoxime Hydrochloride,Cefmenoxime Hydrochloride (2:1),SCE-1365,Abbott 50192,Abbott50192,Hydrochloride, Cefmenoxime,SCE 1365,SCE1365

Related Publications

Y Satoh, and K Ishikawa, and S Iwata, and H Akita, and K Sunakawa
August 1989, The Japanese journal of antibiotics,
Y Satoh, and K Ishikawa, and S Iwata, and H Akita, and K Sunakawa
September 1989, The Japanese journal of antibiotics,
Y Satoh, and K Ishikawa, and S Iwata, and H Akita, and K Sunakawa
September 1989, The Japanese journal of antibiotics,
Y Satoh, and K Ishikawa, and S Iwata, and H Akita, and K Sunakawa
September 1989, The Japanese journal of antibiotics,
Y Satoh, and K Ishikawa, and S Iwata, and H Akita, and K Sunakawa
September 1989, The Japanese journal of antibiotics,
Y Satoh, and K Ishikawa, and S Iwata, and H Akita, and K Sunakawa
August 1989, The Japanese journal of antibiotics,
Y Satoh, and K Ishikawa, and S Iwata, and H Akita, and K Sunakawa
August 1989, The Japanese journal of antibiotics,
Y Satoh, and K Ishikawa, and S Iwata, and H Akita, and K Sunakawa
August 1989, The Japanese journal of antibiotics,
Y Satoh, and K Ishikawa, and S Iwata, and H Akita, and K Sunakawa
May 1991, The Japanese journal of antibiotics,
Y Satoh, and K Ishikawa, and S Iwata, and H Akita, and K Sunakawa
September 1989, The Japanese journal of antibiotics,
Copied contents to your clipboard!